Skip to content
MarketScale
‹ Back to IndustriesHealthcare

What Will It Take to Bring Glioblastoma Research to the Forefront?

Dr. Loralyn Mears is the Director of Scientific Communications for Global Cancer Technology, and she shared her insights about glioblastoma. “Many people have heard of it, especially in light of President Biden now in the office and the loss of his first born son, Beau Biden, six years ago from this dreaded disease. [However], it’s…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Dr. Loralyn Mears is the Director of Scientific Communications for Global Cancer Technology, and she shared her insights about glioblastoma.

“Many people have heard of it, especially in light of President Biden now in the office and the loss of his first born son, Beau Biden, six years ago from this dreaded disease.

[However], it’s not getting the level of attention and support that other cancers do with respect to research, innovation and investment dollars. Why is that?

Well, glioblastoma is a tortuously difficult disease to treat for a number of reasons. First, it’s very difficult to cross the blood brain barrier. That means you have to have drug particles that are so small that they can be transmitted so that they can be effective in their targeted area in the brain.

The second reason why is that the brain is difficult to treat. Will you need it? Well, you may have two lungs and you may be able to remove bits and pieces, but it’s very challenging to remove parts of your brain. It’s all 100% necessary in order to have normal cognitive function.

And the third reason why glioblastoma is very difficult to treat is that it’s an extremely aggressive form of cancer. Fewer than 25% of people survive longer than one year after diagnosis.

So, what can be done? Well, Global Cancer Technology has some new ways of being able to look at this. There is this concept called invisible dots. These are nanoparticles smaller than the naked eye can see, but they can be used as carriers so that, when these carriers are loaded with a payload, which is a cancer inhibitor, for example, they can be directed across the blood brain barrier and attain access to the brain target without compromising the whole function of the brain.

Now, the research is in the early stages, but the bottom line for all of those people and their families affected by glioblastoma is that investments need to be made, new technologies are desperately needed, and the disease and research, although it’s made some progress over the last few years, really has stagnated.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Healthcare AI deployments stall on data quality, not model performance

Healthcare AI deployments stall on data quality, not model performance

Healthcare AI deployments are facing challenges not with the AI models themselves, but with the data quality. Hospital CIOs report difficulties in scaling AI due to fragmented and poorly governed data. This highlights the need for better data management and governance in healthcare AI initiatives.

  • 01Data quality is a major obstacle in scaling healthcare AI deployments.
  • 02Hospital CIOs are encountering issues with fragmented data governance.
  • 03AI model performance is not the primary challenge in these initiatives.

Jul 11, 2026

NHS commits £10bn to health tech, with ambient voice and pathology digitization at the center

NHS commits £10bn to health tech, with ambient voice and pathology digitization at the center

NHS England is investing £10bn in health technology, focusing on ambient voice technology and pathology digitization. This initiative aims to improve healthcare efficiency and patient outcomes. The commitment includes integrating advanced technologies into existing healthcare systems.

  • 01NHS England commits £10bn to health tech.
  • 02Focus areas include ambient voice technology and pathology digitization.
  • 03The initiative aims to enhance healthcare efficiency and patient care.

Jul 9, 2026

Canada launches Vital, a national hospital data platform backed by $210 million, starting with 160 hospitals

Canada launches Vital, a national hospital data platform backed by $210 million, starting with 160 hospitals

Canada has introduced a national hospital data platform named Vital, which will initially connect real-time data from 160 hospitals across three provinces. The initiative is supported by $210 million in funding, with coordination provided by Unity Health Toronto. This platform aims to enhance healthcare data integration and accessibility across the country.

  • 01Vital platform will connect 160 hospitals across three Canadian provinces.
  • 02The initiative is supported by $210 million in funding.
  • 03Unity Health Toronto is coordinating the implementation of this platform.

Jul 8, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub